NEW YORK, July 23, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Becton Dickinson
and Company (NYSE: BDX), Unilife Corporation (NASDAQ: UNIS),
Antares Pharma Inc. (NASDAQ: ATRS), Mindray Medical International
Ltd (NYSE: MR), and DENTSPLY International Inc. (NASDAQ: XRAY).
Free research report on Becton
Dickinson can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=BDX On
Wednesday, July 22, 2015, the NASDAQ
Composite ended at 5,171.77, down 0.70%, the Dow Jones Industrial
Average lost 0.38%, to finish the day at 17,851.04, and the S&P
500 closed at 2,114.15, down 0.24%. The losses were broad based as
six out of nine sectors ended the session in negative. Register for
your complimentary reports at the links given below.
Becton Dickinson and Co.'s stock
edged 0.34% higher, to close Wednesday's session at $148.01. The stock recorded a trading volume of
0.63 million shares, below its three months average volume of 1.00
million shares. Over the last one month and the previous three
months, Becton Dickinson and Co.'s
shares have advanced 3.53% and 2.99%, respectively. Additionally,
the stock has gained 7.25% since the start of this year. The
company is trading 4.37% and 6.94% above its 50-day and 200-day
moving averages, respectively. Furthermore, Becton Dickinson and Co.'s stock traded at a PE
ratio of 27.11 and has a Relative Strength Index (RSI) of 67.02.
Sign up and read the free notes on BDX at:
https://www.EquityResearchInstitute.com/reports?keyword=BDX
Unilife Corp.'s stock finished Wednesday's session 2.58% lower
at $1.89. A total of 1.89 million
shares were traded, which was above its three months average volume
of 0.99 million shares. Over the last one month and the previous
three months, Unilife Corp.'s shares have declined 21.25% and
50.13%, respectively. Additionally, the stock has plummeted 43.58%
since the beginning of 2015. The company's shares are trading below
their 50-day and 200-day moving averages by 20.97% and 42.90%,
respectively. Unilife Corp.'s stock has an RSI of 35.87. The
complimentary notes on UNIS can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=UNIS
On Wednesday, shares in Antares Pharma Inc. ended the session
1.38% lower at $2.14. The stock
reported a trading volume of 0.27 million shares, below its three
months average volume of 0.86 million shares. Antares Pharma Inc.'s
shares have lost 11.20% in the last one month, 23.02% in the
previous three months and 16.73% on YTD basis. The stock is trading
4.35% below its 50-day moving average and 10.47% below its 200-day
moving average. Moreover, shares of Antares Pharma Inc. have an RSI
of 44.63. Register for free on Equity Research Institute and access
the latest research on ATRS at:
https://www.EquityResearchInstitute.com/reports?keyword=ATRS
Mindray Medical International Ltd's stock edged 0.41% lower, to
close the day at $26.87. The stock
recorded a trading volume of 0.14 million shares, much below its
three months average volume of 0.71 million shares. Over the last
one month and over the past three months, Mindray Medical
International Ltd's shares have declined 5.95% and 15.42%,
respectively. However, the stock has advanced 3.29% since the start
of this year. The company's shares are trading 3.47% below their
50-day moving average and 4.98% below their 200-day moving average.
Additionally, Mindray Medical International Ltd traded at a PE
ratio of 16.79 and has an RSI of 46.51. The complete research on MR
is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=MR
On Wednesday, shares in DENTSPLY International Inc. recorded a
trading volume of 0.39 million shares, lower than their three
months average volume of 0.70 million shares. The stock ended the
day 0.84% higher at $52.57. Shares of
the company traded at a PE ratio of 24.11. Although, DENTSPLY
International Inc.'s stock has advanced 0.60% in the past three
months, it has lost 1.44% in the last one month and 1.04% on YTD
basis. The company is trading above its 50-day and 200-day moving
averages by 1.03% and 2.33%, respectively. Furthermore, shares of
DENTSPLY International Inc. have an RSI of 54.94. Free in-depth
research on XRAY is available at:
https://www.EquityResearchInstitute.com/reports?keyword=XRAY
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com